Extreme Heterogeneity Qualified an Acute THC Pressure Estimate in Hypertensive and Stressed Rats

An acute THC pressure reduction pooled from stressed or hypertensive rat models had extremely high heterogeneity. The statistically significant average was not a stable prediction of the response in every model.

The pooled estimate combined different disease conditions

The review grouped rat models of stress and hypertension. It reports a large acute average blood-pressure reduction, with I-squared of 99%. Such marked inconsistency means the individual comparisons varied substantially beyond what sampling error alone would usually explain under the model.

Statistical significance did not remove that variation

A pooled confidence interval can exclude zero while the underlying results remain highly heterogeneous. The average therefore needs its context; it cannot serve as an expected reduction for every rat, much less a patient. The review also reports a chronic-dosing analysis with lower heterogeneity, but that separate result does not repair uncertainty in the acute pool.

The clinical inference remained untested

The experiments did not establish THC as an antihypertensive treatment in humans or supply a safe dose for that purpose. Stress and hypertension models also differ in their mechanisms and baseline conditions. A careful appraisal reports the direction, uncertainty and heterogeneity together. This allows a potentially relevant animal signal to inform research without presenting an unstable cross-model average as a clinical treatment effect.

Related analysis: the study’s broader findings and limitations.

Research cited

Sultan, Millar, O’Sullivan and England (2018). A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ9-Tetrahydrocannabinol.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

The final trial reported that efficacy results for cycles B and C were not analyzed because of substantial crossover. The first-cycle benefit therefore should not be presented as three separately demonstrated cycles of efficacy. Later treatment histories became mixed The study included different continuation and crossover arrangements across its phases….

Spread the love

Read Article: Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

The chemotherapy study permitted capsule adjustment according to nausea and side effects. Active and placebo participants consequently did not take the same median number of capsules per dose. Capsule content and regimen were specified Each active capsule contained 2.5 milligrams of THC and 2.5 milligrams of CBD. Treatment was scheduled…

Spread the love

Read Article: Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

The chemotherapy trial collected both patient-rated cannabinoid-related symptoms and clinician-graded adverse events. Their percentages should not be combined as though they used one severity definition. The assessments used different frameworks Participants completed a structured checklist including sedation, dizziness, anxiety, disorientation, hallucinations and palpitations. Clinicians used the Common Terminology Criteria for…

Spread the love

Read Article: Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us